Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel

Thrombosis and Haemostasis

Volumn 111, Issue 5, 2014, Pages 781-782

  Husted, Steen ^a   De Caterina, Raffaele ^b   Andreotti, Felicita ^c   Arnesen, Harald ^d   Bachmann, Fedor ^e   Huber, Kurt ^f   Jespersen, Jørgen ^g   Kristensen, Steen Dalby ^h   Lip, Gregory Y H ⁱ   Morais, Joao ^j   Rasmussen, Lars H ^k   Siegbahn, Agneta ^l   Storey, Robert F ^m   Weitz, Jeffrey I ⁿ  

^a Hospital Unit West   (Denmark)

^b UNIVERSITY OF CHIETI   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF LAUSANNE   (Switzerland)

^f Wilhelminenhospital   (Austria)

^g UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^h AARHUS UNIVERSITY HOSPITAL   (Denmark)

ⁱ UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^j Cardiology Division Santo Andrés Hospital   (Portugal)

^k AALBORG UNIVERSITY   (Denmark)

^l UPPSALA CLINICAL RESEARCH CENTER   (Sweden)

^m UNIVERSITY OF SHEFFIELD   (United Kingdom)

ⁿ MCMASTER UNIVERSITY   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN ETEXILATE; EDOXABAN; FLUINDIONE; NON VITAMIN K ANTAGONIST ORAL ANTICOAGULANT AGENT; PHENPROCOUMON; RIVAROXABAN; UNCLASSIFIED DRUG; WARFARIN; BLOOD CLOTTING FACTOR; VITAMIN K GROUP;

CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; EDITORIAL; ENZYME ACTIVITY; HEART ATRIUM FIBRILLATION; HUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; VENOUS THROMBOEMBOLISM; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); COMPLICATION; CONTRAINDICATIONS; LIVER DISEASES; METABOLISM; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; RENAL INSUFFICIENCY; THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; BLOOD COAGULATION FACTORS; CLINICAL TRIALS AS TOPIC; HUMANS; LIVER DISEASES; PRACTICE GUIDELINES AS TOPIC; RENAL INSUFFICIENCY; THROMBOEMBOLISM; VITAMIN K;

EID: 84899729145     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH14-03-0228     Document Type: Editorial

References (12)

1. Gallego P, Roldan V, Marin F, et al. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost 2013; 110: 1189-1198.
2. De Caterina R, Husted S, Wallentin L, et al. Vitamin k antagonists in heart disease: Current status and perspectives (section iii). Position paper of the esc working group on thrombosis-task force on anticoagulants in heart disease. Thromb Haemost 2013; 110: 1087-1107.
3. De Caterina R, Husted S, Wallentin L, et al. New oral anticoagulants in atrial fibrillation and acute coronary syndromes: Esc working group on thrombosis-task force on anticoagulants in heart disease position paper. J Am Coll Cardiol 2012; 59: 1413-1425.
4. Ogilvie IM, Newton N, Welner SA, et al. Underuse of oral anticoagulants in atrial fibrillation: A systematic review. Am J Med 2010; 123: 638-645, e634.
5. Wilke T, Groth A, Mueller S, et al. Oral anticoagulation use by patients with atrial fibrillation in germany. Adherence to guidelines, causes of anticoagulation under-use and its clinical outcomes, based on claims-data of 183,448 patients. Thromb Haemost 2012; 107: 1053-1065.
6. De Caterina R, Husted S, Wallentin L, et al. General mechanisms of coagulation and targets of anticoagulants (section i). Position paper of the esc working group on thrombosis--task force on anticoagulants in heart disease. Thromb Haemost 2013; 109: 569-579.
7. Weitz JI, Eikelboom JW, Samama MM. New antithrombotic drugs: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 2012; 141: e120S-151S.
8. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the esc guidelines for the management of atrial fibrillation: An update of the 2010 esc guidelines for the management of atrial fibrillation--developed with the special contribution of the european heart rhythm association. Europace 2012; 14: 1385-1413.
9. Majeed A, Schulman S. Bleeding and antidotes in new oral anticoagulants. Best Pract Res Clin Haematol 2013; 26: 191-202.
10. Heidbuchel H, Verhamme P, Alings M, et al. European heart rhythm association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013; 15: 625-651.
11. Lip GYH, Camm AJ, Hylek EM, et al. Non-Vitamin K Antagonist Oral Anticoagulants: An Appeal for Consensus on Terminology. Chest 2014; Epub ahead of print.
12. De Caterina R, Husted S, Wallentin L, et al. Parenteral anticoagulants in heart disease: Current status and perspectives (section ii). Position paper of the esc working group on thrombosis-task force on anticoagulants in heart disease. Thromb Haemost 2013; 109: 769-786.